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Abstract
Background
Incomplete adherence to tuberculosis (TB) treatment increases the risk of delayed culture
conversion with continued transmission in the community, as well as treatment failure,
relapse, and development or amplification of drug resistance. We conducted a systematic
review and meta-analysis of adherence interventions, including directly observed therapy
(DOT), to determine which approaches lead to improved TB treatment outcomes.
Methods and findings
We systematically reviewed Medline as well as the references of published review articles
for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-
resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as
well as prospective and retrospective cohort studies (CSs) with an internal or external control
group that evaluated any adherence intervention and conducted a meta-analysis of their
impact on TB treatment outcomes. Our search identified 7,729 articles, of which 129 met the
inclusion criteria for quantitative analysis. Seven adherence categories were identified,
including DOT offered by different providers and at various locations, reminders and tracers,
incentives and enablers, patient education, digital technologies (short message services
[SMSs] via mobile phones and video-observed therapy [VOT]), staff education, and combi-
nations of these interventions. When compared with DOT alone, self-administered therapy
(SAT) was associated with lower rates of treatment success (CS: risk ratio [RR] 0.81, 95%
CI 0.73–0.89; RCT: RR 0.94, 95% CI 0.89–0.98), adherence (CS: RR 0.83, 95% CI 0.75–
0.93), and sputum smear conversion (RCT: RR 0.92, 95% CI 0.87–0.98) as well as higher
rates of development of drug resistance (CS: RR 4.19, 95% CI 2.34–7.49). When compared
to DOT provided by healthcare providers, DOT provided by family members was associated
with a lower rate of adherence (CS: RR 0.86, 95% CI 0.79–0.94). DOT delivery in the com-
munity versus at the clinic was associated with a higher rate of treatment success (CS: RR
1.08, 95% CI 1.01–1.15) and sputum conversion at the end of two months (CS: RR 1.05,
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95% CI 1.02–1.08) as well as lower rates of treatment failure (CS: RR 0.56, 95% CI 0.33–
0.95) and loss to follow-up (CS: RR 0.63, 95% CI 0.40–0.98). Medication monitors improved
adherence and treatment success and VOT was comparable with DOT. SMS reminders led
to a higher treatment completion rate in one RCT and were associated with higher rates of
cure and sputum conversion when used in combination with medication monitors. TB treat-
ment outcomes improved when patient education, healthcare provider education, incentives
and enablers, psychological interventions, reminders and tracers, or mobile digital technolo-
gies were employed. Our findings are limited by the heterogeneity of the included studies
and lack of standardized research methodology on adherence interventions.
Conclusion
TB treatment outcomes are improved with the use of adherence interventions, such as
patient education and counseling, incentives and enablers, psychological interventions,
reminders and tracers, and digital health technologies. Trained healthcare providers as well
as community delivery provides patient-centered DOT options that both enhance adherence
and improve treatment outcomes as compared to unsupervised, SAT alone.
Author summary
Why was this study done?
• Tuberculosis remains a global problem and is the leading cause of death from a single
infectious pathogen.
• Tuberculosis treatment involves taking multiple medications daily for months to years,
depending on the level of drug resistance, and failure to complete therapy as prescribed
can lead to poor outcomes, including increased risk of failure, disease relapse, continued
transmission, development of drug resistance, and death.
• Public health programs and researchers have studied different ways of encouraging
patients to take tuberculosis medications as prescribed in order to improve the likeli-
hood of curing patients, but it is unclear which interventions are most effective.
What did the researchers do and find?
• We systematically reviewed all published articles on this topic and found 129 research
studies on different methods to encourage patients to complete tuberculosis treatment.
• We found that providing patients with more support during their treatment increases
the number of patients who successfully complete their treatment and reduces the num-
ber of patients who develop drug-resistant tuberculosis.
• Some of these support measures include different methods of reminding patients to
take their medication doses, such as having a healthcare worker observe them, sending
them reminder text messages, or helping them with financial resources to make it to
their clinic appointments.
Meta-analysis of adherence interventions in TB treatment
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What do these findings mean?
• In addition to prescribing tuberculosis medications to patients with active tuberculosis,
public health programs should include resources to help patients overcome individual
challenges to completing treatment.
• Using financial incentives, tools such as text messaging, and the use of healthcare work-
ers to observe patients taking their medications at home or in the community can help
patients overcome some of the barriers to treatment completion.
• Combining multiple different types of patient-centered support interventions tailored
to an individual’s needs and values can improve tuberculosis control efforts.
Introduction
Adherence to treatment is challenging, given the complexity, modest tolerability, and long
duration of treatment regimens currently available for both drug-susceptible and -resistant
tuberculosis (TB). In turn, low adherence increases the risk of poor outcomes, including treat-
ment failure, relapse, and development or amplification of drug resistance [1–6]. Public health
programs have used a variety of strategies to improve adherence at the health system level via
financial incentives or enablers to offset the cost of accessing treatment, improving coordina-
tion and logistics around TB treatment delivery, and training healthcare providers. Other strat-
egies tackle barriers to completing TB treatment by addressing knowledge gaps, attitudes, and
behaviors surrounding adherence to TB treatment [7–11]. One of the most commonly used
adherence interventions is directly observed therapy (DOT), in which a health worker, family
member, or community member observes the patient taking TB medications [12]. In recent
years, video-observed therapy (VOT) has gained attention as an alternative way of delivering
DOT [13,14]. Other interventions aimed at supporting adherence through DOT include
incentives, which are material or financial rewards provided to those adhering treatment [15],
and enablers, which are interventions that allow patients to overcome economic constraints
associated with DOT, such as absence from work or the direct and indirect patient costs of
accessing TB treatment. Other interventions focus on providing education on TB, its treat-
ment, and prevention to help patients make informed decisions and the healthcare team to
deliver patient-centered care [16]. Reminder systems and patient tracers are targeted at assist-
ing patients to keep appointments and to take action when patients miss appointments [17].
These interventions include reminder letters, phone calls, home visits, and, more recently,
short message service (SMS) technology as well as electronic pill boxes. Psychological interven-
tions aim to support via psychological or emotional counseling or a social network of peers
undergoing TB treatment as a means of improving adherence to TB treatment [18,19]. Given
the significant losses patients and the health system incur as a result of poor TB treatment out-
comes, identifying those interventions that are most likely to improve adherence and out-
comes, especially in resource-limited settings, is crucial.
The first pillar of the End TB Strategy of the World Health Organization (WHO)—Inte-
grated, Patient Centered Care and Prevention—calls for “treatment of all people with
tuberculosis including drug-resistant tuberculosis; and patient support” [20]. In 2015, WHO
commissioned a series of systematic reviews and meta-analyses ahead of a Guideline Develop-
ment Group meeting tasked with the revision of its TB treatment guidelines in accordance
Meta-analysis of adherence interventions in TB treatment
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with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
approach [21–23]. Until then, no evidence-based recommendations on TB treatment adher-
ence and delivery existed. In order to inform this process, we conducted a systematic review
and meta-analysis of studies of adherence interventions on drug-susceptible and -resistant
TB treatment outcomes. Our goal was to identify any adherence interventions associated with
improvement in TB treatment outcomes.
Methods
Search strategy and selection criteria
This study has been designed and reported according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analysis (PRISMA, S1 Text). The full protocol for this study is
available in the supplementary material (S2 Text).
We included all randomized controlled trials (RCTs) as well as prospective and retrospec-
tive cohort studies (CSs). The population of interest included all adults or children in any set-
ting undergoing active TB treatment. This included patients with pulmonary, extrapulmonary,
smear-positive or -negative, and drug-susceptible and -resistant TB as well as patients with
HIV coinfection. To be included, studies must have had an intervention targeted to increase
adherence to TB treatment and an internal or historical control group (Table 1). We excluded
articles on patients with only latent TB infection. We also excluded studies that compared
DOT delivered in a hospital versus clinic setting because of a separate focused systematic
review being conducted at the time of this review.
The following were the primary outcomes of interest as defined by WHO [25]: Cure, a pul-
monary TB patient with bacteriologically confirmed TB at the beginning of treatment who was
smear or culture negative in the last month of treatment and on at least one previous occasion;
Treatment completion, a TB patient who completed treatment without evidence of failure but
with no record to show that sputum smear or culture results in the last month of treatment
and on at least one previous occasion were negative, either because tests were not done or
because results are unavailable; Treatment success, the sum of “cure” and “treatment comple-
tion”; Treatment failure, a TB patient whose sputum smear or culture is positive at month 5 or
later during treatment; Death, a TB patient who dies for any reason before starting or during
the course of treatment; Loss to follow-up, a TB patient who did not start treatment or whose
treatment was interrupted for two consecutive months or more; Relapse, a patient with a
bacteriologically positive sputum smear or culture after the completion of any of the study TB
Table 1. PICO question breakdown for adherence interventions in TB treatment.
Population Intervention Comparator Outcome
Patients on treatment for drug-
sensitive TB
Patients on MDR-TB treatment
Children (0–14 y) and adults
TB patients infected with HIV
and not infected with HIV
Any intervention to promote treatment adherence
• Supervising treatment (DOT, VOT)
• Measures to improve treatment adherence (e.g.,
medication monitors and/or SMS or phone call
reminders)
• Social support (educational, psychological, material)
• Combinations of the above interventions
Routine
practice
• Adherence to treatment (or treatment
interruption because of nonadherence)
• Conventional TB treatment outcomes: cured/
completed, failure, relapse, survival/death
• Adverse reactions from TB drugs (severity, type,
organ class)
Routine practice refers to regular TB drugs pickup and consultations with a physician or other healthcare workers being available when necessary, TB treatment being
free of charge; and essential information/health education in relation to TB treatment being provided [24].
Abbreviations: DOT, directly observed therapy; MDR-TB, multidrug-resistant tuberculosis; PICO, population, intervention, comparison, outcome; SMS, short message
service; TB, tuberculosis; VOT, video-observed therapy.
https://doi.org/10.1371/journal.pmed.1002595.t001
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regimens; Adherence, defined using parent study definitions such as being lost to follow-up
(or default), isoniazid (INH) urine test, appointment keeping, etc.; and Development of resis-
tance, identification of new drug resistance in a subsequent isolate otherwise matched with the
baseline isolate. In post hoc analyses, given the number of articles that defined adherence as
having taken more than 80%–90% of treatment doses, and for ease of comparison between
studies, we chose to use this definition for the outcome of adherence when available.
We searched the literature using Medline with two search strategies, one to include all types
of adherence interventions and the second targeted at SMS/VOT through February 3, 2018.
The complete search strategy is available in S1 and S2 Tables. We also reviewed references of
relevant articles and systematic reviews and contacted experts in the field for unpublished
studies. We included all studies in the English language regardless of publication status or
date. However, two foreign language articles were included, as data from them were previously
abstracted by a different systematic review. Titles and abstracts were reviewed by one investi-
gator (NA) and full manuscript content reviewed by multiple investigators (NA, PN, LJ, CM).
Ethics approval was not required for this study, as all information was abstracted from pub-
lished literature without access to any individual and/or identifiable data.
Data extraction and variable definitions
Using a standard data abstraction sheet, the following data were recorded from articles that
met our inclusion criteria: patient selection, type of TB (pulmonary or extrapulmonary), HIV
coinfection, treatment outcomes, method of blinding and randomization, results of drug-
susceptibility testing, acid-fast bacilli (AFB) smear and culture results, mode of supervision
of therapy, type of adherence intervention, and study results for the outcomes of interest
(adjusted or unadjusted risk ratios [RRs], risk differences [RDs], raw data). We chose to use
unadjusted RRs preferentially if these data were available. When available, data were gathered
from both per protocol and intention-to-treat analyses. The quality of the studies was assessed
using the Cochrane Risk of Bias tool for RCTs, and the Newcastle-Ottawa Scale was used for
observational studies [26,27].
We grouped the adherence interventions identified across studies into the following
categories: (1) DOT referred to the act of observing a patient swallow medications, and self-
administered therapy (SAT) was defined as the patient taking each medication dose without
supervision; (2) education and counseling interventions were those aimed at providing ade-
quate knowledge and ensuring patient understanding of the disease process and risks and
benefits associated with treatment adherence; (3) incentives were interventions to promote
treatment adherence through a financial or material reward and enablers were interventions
that allowed patients to overcome barriers to treatment adherence (cost, distance, availability);
(4) reminders included any intervention made prior to the patient taking medications or
attending appointments to serve as a reminder and tracers involved contacts made after
a patient had failed adherence in order to improve subsequent adherence to treatment; (5)
psychological interventions aimed to provide emotional or psychological support aimed
at reducing stigma and increasing treatment adherence; (6) digital health interventions
included any of the above categories implemented via mobile electronic devices (SMS, VOT,
medication monitors); and lastly, (7) mixed interventions included a combination of the afore-
mentioned interventions to address barriers to adherence based on patient-specific needs and
values. Thus, the term “patient-centered DOT” or “enhanced DOT” was used to designate any
study using adherence interventions spanning the multiple categories mentioned above in
conjunction with DOT. With respect to DOT provider type, a lay provider was defined as an
untrained volunteer, including family members or other patient-designated person. A trained
Meta-analysis of adherence interventions in TB treatment
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health worker included any health worker, community member, or volunteer who had
received any form of formal training for DOT. For the categories of patient education and
counseling, staff education, incentives and enablers, reminders and tracers, and psychological
interventions, studies included in the meta-analysis had to have employed the same supervi-
sion modality (either DOT or SAT) for both the intervention and control arms.
All estimates of effect for dichotomous outcomes were reported as RRs with 95% confi-
dence intervals. When two or more studies were available on a particular outcome, random
effects meta-analysis was performed to obtain a pooled estimate of treatment effect and pooled
RR between the intervention and control arms. Heterogeneity was assessed visually using for-
est plots and statistically using the χ2 and I2 tests. If more than 10 studies were available for a
particular comparison, we used funnel plots to determine publication bias. All analyses were
conducted in RevMan5 [28]. All figures were generated using RevMan and GraphPad Prism
7.0 [29]. If a study reported no events in the intervention or control group for an outcome of
interest, the RD was calculated.
Results
Title and abstract literature review yielded 7,729 articles, of which 1,092 met the inclusion cri-
teria for full text review (Fig 1). References of 32 systematic reviews found through our online
search were also reviewed for relevant articles. A final 129 articles met the inclusion criteria
for quantitative analysis. Characteristics of included studies as well as quality assessments are
summarized in S3 Table, S1 and S2 Figs. The overall quality of included studies varied signifi-
cantly amongst CSs. The quality of RCTs was limited predominantly by lack of blinding, given
the nature of adherence interventions. Below is a brief summary of findings by each type of
adherence intervention (Table 2). When available, data from RCTs and CSs are listed in
Fig 1. PRISMA summary. TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002595.g001
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Fig 2. (A) SAT compared with DOT on TB treatment outcomes. (B) Impact of any DOT provided by lay providers, family members, or
healthcare workers on TB treatment outcomes.  = significant heterogeneity in the meta-analysis as determined by I2 statistic.
1 = depicted is the rate of adherence in one study defined as completing>90% of treatment doses by pill counting in one CS and based
on six positive INH urine tests done at random in one RCT. Conversion = sputum conversion to negative at the end of two months (CS)
and three months (RCT). N = number of studies included within the meta-analysis. Resistance = development of drug resistance. CS,
cohort study; DOT, directly observed therapy; HCW, healthcare worker; INH, isoniazid; LTFU, loss to follow-up; RCT, randomized
controlled trial; RR, risk ratio; SAT, self-administered therapy; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002595.g002
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parentheses. Some of the analyses contained significant heterogeneity, as measured by I2,
which has been denoted on their corresponding figures.
SAT versus DOT
Forty-six studies were included in the meta-analysis, seven of which were RCTs [4,30–74]. Six
CSs included primarily HIV/TB patients [51,53–55,57,72] and two CSs involved primarily
MDR-TB patients [56,72]. DOT was offered daily or intermittently at home, clinic, or in the
community. DOT providers ranged from family members to trained lay providers and health-
care providers.
Compared to those undergoing any DOT, participants who received SAT had a lower rate
of treatment success (16 CSs: RR 0.81, 95% CI 0.73–0.89; 5 RCTs: RR 0.94, 95% CI 0.89–0.98),
cure (18 CSs: RR 0.64, 95% CI 0.54–0.76; 4 RCTs: 0.98, 95% CI 0.83–1.17), and adherence (1
CS: RR 0.84, 95% CI 0.75–0.93; 1 RCT: RR 0.94, 95% CI 0.87–1.02) (Figs 2–5). One RCT found
a lower rate of smear conversion at the end of two months amongst SAT patients (RR 0.92,
95% CI 0.87–0.98) (Fig 6). There was no significant difference between DOT and SAT
amongst all CSs and RCTs for the outcomes of mortality (23 CSs, 4 RCTs), treatment comple-
tion (14 CSs, 5 RCTs), treatment failure (15 CSs, 5 RCTs), loss to follow-up (21 CSs, 4 RCTs),
relapse (6 CSs, 1 RCT), or development of drug resistance (3 CSs) (S3–S14 Figs).
Fig 3. Funnel plot of cohort studies comparing treatment success rates in patients undergoing SAT versus DOT. No funnel plot of RCTs has been
included as there were fewer than 10 RCTs. DOT, directly observed therapy; RCT, randomized controlled trial; RR, risk ratio; SAT, self-administered
therapy; SE, standard error.
https://doi.org/10.1371/journal.pmed.1002595.g003
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An assessment of the publication bias (S3, S5, S7, S9 and S11 Figs) showed asymmetry for
the outcomes of mortality, treatment success, and loss to follow-up. Notably, a few smaller
studies found worse outcomes with SAT, as compared with DOT. The plots reflect the signifi-
cant heterogeneity between the studies and may also be suggestive of publication bias (i.e.,
reporting bias in CSs).
Fig 4. Meta-analysis of treatment success rates in patients undergoing SAT versus DOT. DOT, directly observed therapy; M-H, Mantel-Haenszel;
SAT, self-administered therapy.
https://doi.org/10.1371/journal.pmed.1002595.g004
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In patients with HIV/TB, SAT was associated with lower rates of treatment success (3 CSs:
RR 0.41, 95% CI 0.29–0.59), completion (1 CS: RR 0.10, 95% CI 0.01–0.76), and cure (2 CSs:
RR 0.40, 95% CI 0.29–0.55) as well as a higher rate of mortality (4 CSs: RR 2.38, 95% CI 1.44–
3.92). The difference in the rates of loss to follow-up (3 CSs: RR 1.33, 95% CI 0.72–2.48), treat-
ment failure (2 CSs: RR 1.96, 95% CI 0.61–6.32), and relapse (1 CS: RR 0.90, 95% CI 0.13–
6.28) between the two groups (Figs 2, 7 and S16–S20 Figs) was not significant. Although sev-
eral studies in our meta-analysis included patients with MDR-TB in their cohort, all but two
reported aggregate data on treatment outcomes without stratifying by drug-resistant status. Of
Fig 5. Forest plot of adherence rates in studies comparing patients undergoing SAT versus DOT. CHW, community health worker; DOT, directly
observed therapy; INH, isoniazid; M-H, Mantel-Haenszel; SAT, self-administered therapy.
https://doi.org/10.1371/journal.pmed.1002595.g005
Fig 6. Meta-analysis of rates of sputum conversion in patients undergoing SAT versus DOT. DOT, directly observed therapy; M-H, Mantel-
Haenszel; RCT, randomized controlled trial; SAT, self-administered therapy.
https://doi.org/10.1371/journal.pmed.1002595.g006
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the 28 MDR-TB patients in one retrospective CS in New York City from 1987–1997 [56], 11
underwent SAT and 17 received DOT. The mortality, treatment completion, and nonadher-
ence rates were not significantly different between the two groups (S21–S24 Figs). A prospec-
tive CS in South Africa of rifampicin-resistant patients found no evidence of a difference in
rates of mortality, treatment failure, and loss to follow-up between those undergoing DOT
for the entire duration of TB treatment and those who only received DOT during the first six
months [72].
DOT provider type
Seven CSs compared treatment outcomes in patients who received DOT by family/lay provid-
ers or healthcare workers [42,49,63,75–78]. Family member DOT was associated with a lower
rate of adherence (1 CS: RR 0.86, 95% CI 0.79–0.94) and higher rate of treatment failure (3
CSs: RR 1.79, 95% CI 1.08–2.98) compared with trained health worker DOT (Fig 2). There was
no evidence of a difference in rates of treatment success, completion, cure, mortality, and loss
to follow-up between the two groups (Figs 2, 8, 9 and S25–S29 Figs). DOT by lay providers
showed no significant difference in outcomes when compared with healthcare worker (HCW)
DOT.
DOT locations
Four RCTs and 21 CSs compared DOT offered at different locations, including the home,
community, and clinic [37,39,42,49,61,73,79–97]. In comparison with clinic-based DOT, treat-
ment in the community was associated with higher rates of treatment completion (1 RCT: RR
2.92, 95% CI 1.15–7.41; 3 CSs: RR 0.87, 95% CI 0.87–1.09) and sputum conversion at the end
of two months (2 CSs: RR 1.05, 95% CI 1.02–1.08; 1 RCT: RR 1.09, 95% CI 0.99–1.22) as well
as lower rates of loss to follow-up (6 CSs: RR 0.63, 95% CI 0.40–0.98; 2 RCTs: RR 1.04, 95% CI
0.34–3.19), treatment failure (6 CSs: RR 0.56, 95% CI 0.33–0.95; 1 RCT: RR 0.68, 95% CI 0.13–
3.69), and unfavorable outcome (1 CS: RR 0.63, 95% CI 0.55–0.73) (Figs 10–13 and S30–S35
Figs). No significant differences were noted for the outcomes of mortality or cure. Home-
based DOT was associated with a lower rate of treatment adherence when compared with
clinic-based DOT in one CS, in which patients were observed by family members or lay pro-
viders (1 CS: RR 0.86, 95% CI 0.79–0.94), while another found no significant difference in
adherence rates when comparing home and clinic based DOT. Home-based DOT was
Fig 7. Meta-analysis of treatment success rates in HIV/TB patients undergoing SAT versus DOT. DOT, directly observed therapy; M-H, Mantel-
Haenszel; SAT, self-administered therapy; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002595.g007
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associated with a higher mortality rate (8 CSs: RR 1.86, 95% CI 1.34–2.59). This effect is nulli-
fied with the removal of the study by Mhimbira and colleagues, who defined home-based
DOT as DOT delivered at home by a treatment supporter of patients’ choosing. When com-
pared with a particular type of community-based DOT that included offering a free lunch to
patients, home-based DOT had a lower success rate in one CS (1 CS: RR 0.94, 95% CI 0.92–
0.98; 2 RCTs: RR 1.02, 95% CI 0.94–1.11) but no significant difference in rates of treatment
completion, cure, mortality, failure, and loss to follow-up in other studies. Home-based DOT
was associated with marginally higher rates of sputum conversion at two months, when com-
pared with clinic-based DOT (3 CSs: RR 1.24, 95% CI 1.01–1.54).
Patient education and counseling
Four RCTs and one CS evaluated the effect of oral and written educational material as well as
counseling on TB treatment outcomes [7–11]. Education and counseling was associated with
a higher rate of treatment completion (1 RCT: RR 1.71, 95% CI 1.32–2.22), cure (1 RCT: RR
2.15, 95% CI 1.58–2.92), and adherence (1 RCT: RR 1.83, 95% CI 1.14–2.92; 1 CS: RR 1.21,
Fig 9. Comparison of adherence rates in patients receiving DOT by a family member versus HCW. DOT, directly observed therapy; HCW,
healthcare worker; M-H, Mantel-Haenszel.
https://doi.org/10.1371/journal.pmed.1002595.g009
Fig 8. Meta-analysis of treatment success rates in patients receiving DOT by different types of providers. DOT, directly observed therapy; HCW,
healthcare worker; M-H, Mantel-Haenszel.
https://doi.org/10.1371/journal.pmed.1002595.g008
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Fig 10. (A) Impact of DOT provided at home, in the community, or in clinic on TB treatment outcomes. (B) Impact of patient
education and counseling interventions on TB treatment outcomes.  = significant heterogeneity in the meta-analysis, as determined by
I2 statistic. 1 = adherence defined as the proportion of patients that took>75% of prescribed doses in one CS and the proportion of
patients attending all appointments in one RCT. Conversion = sputum conversion to negative at the end of two months. N = number of
studies included within the meta-analysis. Composite outcome reported by one study defined as combined failure, default, death, or
transfer out. CS, cohort study; DOT, directly observed therapy; LTFU, loss to follow-up; RCT, randomized controlled trial; RR, risk
ratio; TB, tuberculosis; UO, unfavorable outcome.
https://doi.org/10.1371/journal.pmed.1002595.g010
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95% CI 1.05–1.40) (Figs 10, 14, 15 and S36–S40 Figs). These interventions had no meaningful
impact on rates of mortality, treatment success, failure, or loss to follow-up.
Incentives and enablers
Incentives and enablers in four RCTs and eleven CSs were associated with lower rates of mor-
tality (3 CSs: RR 0.51, 95% CI 0.37–0.71; 2 RCTs: RR 0.93, 95% CI 0.41–2.09), treatment failure
(1 RCT: RR 0.66, 95% CI 0.50–0.87; 2 CSs: RR 0.18, 95% CI 0.02–2.10), and loss to follow-up
Fig 11. Meta-analysis of treatment success rates in patients receiving DOT in various locations. DOT, directly observed therapy; HCW, healthcare
worker; M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g011
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Fig 13. Meta-analysis of sputum conversion rates at two months in patients receiving DOT at various locations. DOT, directly observed therapy;
M-H, Mantel-Haenszel.
https://doi.org/10.1371/journal.pmed.1002595.g013
Fig 14. Meta-analysis of treatment success rates in patients receiving patient education and counseling interventions in addition to standard care
versus standard care alone. M-H, Mantel-Haenszel.
https://doi.org/10.1371/journal.pmed.1002595.g014
Fig 12. Adherence rates in patients receiving DOT at various locations. DOT, directly observed therapy; M-H, Mantel-Haenszel.
https://doi.org/10.1371/journal.pmed.1002595.g012
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(1 RCT: RR 0.74, 95% CI 0.60–0.90; 5 CSs: RR 0.48, 95% CI 0.28–0.81) as well as higher rates
of treatment success (3 RCTs: RR 1.07, 95% CI 1.03–1.11; 4 CSs: RR 1.25, 95% CI 1.09–1.42),
completion (2 RCTs: RR 1.23, 95% CI 1.15–1.31; 4 CSs: RR 1.18, 95% CI 0.97–1.43), cure (4
CSs: 1.13, 95% CI 1.02–1.26; 1 RCT: RR 0.92, 95% CI 0.85–1.01), and sputum conversion at
two months (1 RCT: RR 1.21, 95% CI 1.02–1.43). (Figs 16, 17 and S41–S47 Figs) [83,98–111].
Reminders and tracers
Nine RCTs and six CSs found higher rates of treatment success (4 RCTs: RR 1.14, 95% CI
1.02–1.28; 2 CSs: RR 1.12, 95% CI 1.00–1.26), cure (2 CSs: RR 2.16, 95% CI 1.63–2.85; 2 RCTs:
RR 1.22, 95% CI 0.78–1.90), adherence (1 RCT: RR 1.65, 95% CI 1.21–2.25), and sputum con-
version at two months (3 RCTs: RR 1.29, 95% CI 1.12–1.50) and lower rates of development of
drug resistance (1 CS: RR 0.50, 95% CI 0.45–0.55) and loss to follow-up (4 CSs: RR 0.77, 95%
CI 0.69–1.13; 4 RCTs: RR 0.69, 95% CI 0.42–1.13) with the use of reminders and tracers (Figs
16, 18–20 and S48–S55 Figs) [112–126]. One study by Bronner and colleagues was removed in
sensitivity analyses due to lack of controlling for baseline differences in treatment outcomes
prior to intervention in the intervention and control districts (Fig 18).
Staff education
Three RCTs and one CS involved interventions such as adherence education for staff, peer
training for lay health workers, reminders to initiate adherence discussions, and educational
tools and aids for decision-making [127–130]. These interventions were associated with higher
rates of treatment success (1 CS: RR 1.34, 95% CI 1.15–1.55) and lower rates of loss to follow-
up (1 CS: RD −0.18, 95% CI −0.26–−0.10) in the one CS. The three RCTs found no significant
difference in rates of TB treatment outcomes with the use of such interventions (Figs 21, 22
and S56–S61 Figs).
Psychological interventions
One RCT focused on brief counseling interventions for alcohol cessation and another offered
self-help groups [131,132]. One prospective CS evaluated the impact of TB clubs as a support
network [133]. Support groups were associated with higher rates of treatment completion (1
CS: RR 1.47, 95% CI 1.08–2.00; 1 RCT: RR 1.20, 95% CI 1.03–1.39) and lower rates of treat-
ment failure (1 RCT: RD −0.12, 95%CI −0.22–−0.01; 1 CS: RD −0.02, 95% CI −0.06–0.03) and
loss to follow-up (1 CS: RR 0.31, 95% CI 0.15–0.63; 1 RCT: RR 0.50, 95% CI 0.05–5.31) (Fig 21
and S62–S67 Figs).
Fig 15. Adherence rates in patients receiving patient education and counseling interventions in addition to standard care versus standard care
alone. M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g015
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Fig 16. (A) Impact of incentives and enablers on TB treatment outcomes. (B) Impact of reminders and tracers on TB treatment
outcomes.  = significant heterogeneity in the meta-analysis as determined by I2 statistic. 1 = adherence defined as the proportion of
patients who presented for all drug collections in the first six months of treatment. Conversion = sputum conversion at the end of two
months. Resistance = development of drug resistance. N = number of studies included within the meta-analysis. LTFU, loss to follow-up;
RCT, randomized controlled trial; RR, risk ratio; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002595.g016
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Digital health
Five RCTs and two CSs looked at daily reminder texts or phone call reminders to take medica-
tions for patients undergoing SAT or family DOT [114,117,119,120,125,126,134]. Two CSs
evaluated the impact of VOT [135,136]. In one RCT comparing SMS reminders in patients
undergoing SAT versus those undergoing DOT, SAT patients had a higher treatment comple-
tion rate (1 RCT: RR 1.11, 95% CI 1.04–1.18). One CS on patients using a combination wireless
pill box/SMS reminder system found higher rates of cure (RR 2.32, 95% CI 1.60–3.36) and spu-
tum conversion at two months (RR 1.62, 95% CI 1.09–2.42) compared to those without this
system. Other studies found no difference in rates of mortality, treatment success, failure, or
loss to follow-up (Figs 23–25 and S68–S74 Figs).
Electronic medication monitor boxes were associated with lower rates of loss to follow-up
(1 CS: RR 0.59, 95% CI 0.43–0.80), poor outcome (1 CS: RR 0.63, 95% CI 0.47–0.83), and poor
adherence (1 CS: RR 0.57, 95% CI 0.53–0.61). Phone reminders and medication monitor
boxes combined were associated with lower rates of poor adherence (1 CS: RR 0.56, 95% CI
0.52–0.60). Compared with DOT, VOT rates of treatment completion (2 CSs: RR 1.17, 95%
CI 0.79–1.72) and mortality (1 CS: RR 1.80, 95% CI 0.19–17) were not significantly different
[135,136].
Mixed interventions
Seven RCTs and eleven CSs combined multiple adherence interventions from the aforemen-
tioned categories to DOT or SAT [10,59,137–152]. Patient-centered DOT (enhanced DOT)
was associated with lower rates of loss to follow-up (4 RCTs: RR 0.45, 95% CI 0.32–0.65) and
higher rates of treatment success (3 CSs: RR 1.27, 95% CI 1.09–1.49; 2 RCTs: RR 1.16, 95% CI
1.11–1.22) and cure (3 RCTs: RR 1.19, 95% CI 1.13–1.25) when compared with DOT alone
(Figs 23, 26, 27 and S75–S82 Figs). When compared with SAT, patient-centered DOT was
associated with higher rates of treatment success (2 CSs: RR 1.22, 95% CI 1.16–1.27; 1 RCT:
RR 1.36, 95% CI 1.06–1.75), treatment completion (2 CSs: RR 1.84, 95% CI 1.52–2.21; 1 RCT:
RR 1.41, 95% CI 1.11–1.79), cure (2 CSs: RR 1.42, 95% CI 1.02–1.99; 1 RCT: RR 1.36, 95% CI
Fig 17. Meta-analysis of treatment success rates in patients receiving incentives and enablers in addition to standard care versus standard care
alone. M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g017
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Fig 18. (A) Meta-analysis of treatment success rates in patients receiving reminders/tracers in addition to standard care versus standard care alone. (B)
Sensitivity analysis: removing the heaviest weighted study (Bronner 2012) in which control and intervention cohorts had different pre-intervention
success rates. M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g018
Fig 19. Adherence rates in patients receiving reminders/tracers in addition to standard care versus standard care alone. M-H, Mantel-Haenszel;
RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g019
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1.06–1.75), and sputum conversion at two months (1 RCT: RR 1.65, 95% CI 1.16–2.34). We
did not find any studies that compared patient-centered DOT to patient-centered SAT.
Discussion
To our knowledge, this is the first comprehensive systematic review of prospective and retro-
spective CSs as well as RCTs studying any interventions used to increase adherence to treat-
ment of either drug-susceptible or -resistant TB. The studies included represent high- and
low-resource settings and therefore are broadly representative across a variety of TB program
settings. Our meta-analysis identified several adherence interventions that consistently showed
associations with improved adherence and TB treatment outcomes. Of note, DOT was associ-
ated with better treatment outcomes compared to SAT, especially for TB patients living with
HIV. The addition of other adherence interventions to DOT, such as education (for staff or
patients), material or psychological support, or reminder systems (including SMS technology
and phone reminders), correlated with reduced rates of mortality and loss to follow-up and
higher rates of treatment success and cure. Combining other types of adherence interventions
with DOT or SAT was associated with improved outcomes compared to either treatment
modality alone. Lastly, VOT had no evidence of a difference in rates of treatment completion
and mortality when compared to DOT.
Our conclusions differ from prior reviews. Karumbi and colleagues focused on data from
RCTs and concluded that DOT did not improve TB treatment completion and cure when
compared to self-administered therapy [153]. When our meta-analysis was limited to datasets
from RCTs, we found similar results on these outcomes. Whereas RCTs are a superior study
design because of their strong internal validity, they can lack external validity [154–156]. For
example, RCTs provide rigorous oversight of participants that does not correspond to routine
practice in program settings. Furthermore, without allocation concealment, alterations of
behavior because of the awareness of being observed can further hamper the ability of RCTs to
assess the value of adherence interventions. Another review by Pasipanodya and colleagues
included RCTs as well as prospective CSs and concluded that DOT was not significantly better
than SAT in preventing microbiologic failure, relapse, or development of drug resistance
[157]. Our review found similar results with respect to these particular outcomes of interest.
However, because our inclusion criteria were broader than these three outcomes, we included
a larger number of CSs and RCTs in our review, resulting in a larger dataset for analysis.
Important findings in our analysis are that a variety of adherence interventions are effective
in improving TB outcomes, certain subpopulations are more likely to benefit from particular
Fig 20. Meta-analysis of rates of sputum conversion at two months in patients receiving reminders/tracers in addition to standard care versus
standard care alone. M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g020
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Fig 21. (A) Impact of staff education on TB treatment outcomes. (B) Impact of using psychological interventions, such as mental health
counseling and support groups, on TB treatment outcomes.  = significant heterogeneity in the meta-analysis, as determined by I2
statistic. N = number of studies included within the meta-analysis. CS, cohort study; LTFU, loss to follow-up; RCT, randomized
controlled trial; RR, risk ratio; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002595.g021
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types of interventions (i.e., DOT for TB patients with HIV), and certain modalities of DOT are
more effective than others. Furthermore, treatment supervision alone in the form of DOT is
not likely to guarantee improved TB treatment outcomes in all TB patients across all settings.
As such, a patient-centered care approach to TB adherence using a package of interventions
tailored to a patient’s needs and values is more likely to improve TB outcomes. It must be
noted that most of the literature on adherence interventions included in our meta-analysis did
not evaluate the impact of adherence interventions on relapse and development of drug resis-
tance, which are critical outcomes of interest for population-level TB management [2]. Only
three CSs compared the impact of DOT on the development of drug resistance compared with
SAT, one of which found no significant difference [4,59,70]. One CS found reminders corre-
lated with reduced rates of drug resistance [113], and another CS on incentives found no bene-
fit [109]. With regard to relapse rates, one RCT [158] and four CSs [40,54,59,67] found no
significant differences between DOT and SAT, while two CSs saw a decline in relapse rates
with DOT [4,38]. Lastly, relapse rates were similar between patient-centered DOT and SAT in
one CS [59]. Given the paucity of data on such critical outcomes, the effectiveness of adherence
interventions based on our analyses should be assessed cautiously.
DOT has several limitations, including the cost imposed on patients and the health system
[33–35,49,159,160]. Furthermore, WHO’s guidance on TB ethics argues that DOT is only
ethically justifiable in the context of a patient-centered approach and provides an ethical
framework for its implementation [161,162]. It must be noted that many of the adherence
interventions in these studies involve significant resource utilization, which makes it necessary
to mobilize the resources needed to facilitate their implementation. Comparing the cost-effec-
tiveness of different adherence interventions would be crucial to strengthen and expand
patient-centered approaches for adherence to TB treatment. Data from studies on digital tech-
nology and VOT are promising and have the potential to reduce costs to the patient and the
health system [163]. The key challenges to address in implementing SMS and VOT adherence
interventions are ensuring access to smartphones, coverage of data transmission costs, data
encryption, and patient privacy.
Our meta-analysis has limitations. First, most of the studies on DOT in TB patients living
with HIV are from the pre-ART era or were conducted in patients at highest risk of loss to
follow-up. Contemporary, more integrated approaches to HIV/TB care were not assessed in
this review. Second, the studies in our review were heterogeneous in their methodology. It is
Fig 22. Meta-analysis of the impact of staff education on treatment success rates. M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g022
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Fig 23. (A) Impact of digital technologies on TB treatment outcomes. (B) Impact of combining different types of adherence interventions
on TB treatment outcomes.  = significant heterogeneity in the meta-analysis, as determined by I2 statistic. 1 = defined as proportion of
patients taking>90% of pills. Conversion = sputum conversion at the end of two months. N = number of studies included within the
meta-analysis. Poor adherence = percentage of patient-months in which>20% of doses were missed. CS, cohort study; DOT, directly
observed therapy; LTFU, loss to follow-up; RCT, randomized controlled trial; RR, risk ratio; TB, tuberculosis; VOT, video-observed
therapy.
https://doi.org/10.1371/journal.pmed.1002595.g023
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difficult to standardize methodology in these types of studies, given the numerous disparate
interventions possible, evolving technologies, and the complexities of behavior change. We
grouped similar interventions within categories of adherence interventions to draw on their
similarities for practice recommendations. As the way in which such interventions are imple-
mented largely determines their success, inter-study variability impacts our meta-analytic
findings. Third, our literature review was restricted to English language articles in Medline.
The absence of potentially relevant studies published in non-English language journals or via
other electronic databases is a limitation. However, we reviewed the references of 32 systematic
reviews on this topic with search strategies that spanned European (Embase), Latin American
(LILACS), Cochrane Central Register of Controlled Trials (CENTRAL), and metaRegister of
Controlled Trials (mRCT) databases. Additionally, we consulted experts in studies of adher-
ence interventions to ascertain that all relevant studies were included. Lastly, the results from
meta-analyses of CSs should be interpreted with caution given uncontrolled confounding
inherent to such studies, as noted by our quality assessment.
In this review, we sought to evaluate the impact of adherence interventions in the treat-
ment of drug-resistant TB, and whereas some of the studies included in our review had
cohorts of patients with drug resistance, no studies focused only on MDR-TB met our inclu-
sion criteria. A systematic review in 2009 that was limited to case series without an internal
or historic control group found that rates of treatment success were higher in patients with
MDR-TB who received DOT throughout treatment than those who did not [164]. Another
meta-analysis also limited to case series found lower rates of loss to follow-up with DOT
delivery at home, use of community health workers for DOT (as opposed to nurses or
Fig 24. Meta-analysis of treatment success rates in patients receiving phone reminders in addition to standard care versus standard care alone.
M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g024
Fig 25. Rates of sputum conversion at two months in patients receiving phone reminders in addition to standard care versus standard care alone.
M-H, Mantel-Haenszel; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1002595.g025
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healthcare providers), a standardized treatment regimen, provision of DOT throughout
treatment, and patient education [165]. Given the increased length and duration of treat-
ment necessary for patients with MDR-TB, more studies on adherence interventions tailored
to this population are needed.
Fig 26. Meta-analysis of treatment success rates in patients receiving combination adherence interventions (enhanced DOT) in addition to
standard care versus standard care alone. DOT, directly observed therapy; M-H, Mantel-Haenszel; RCT, randomized controlled trial; SAT, self-
administered therapy.
https://doi.org/10.1371/journal.pmed.1002595.g026
Fig 27. Adherence rates in patients receiving combination adherence interventions (enhanced DOT or enhanced SAT) in addition to standard
care versus standard care alone. DOT, directly observed therapy; M-H, Mantel-Haenszel; RCT, randomized controlled trial; SAT, self-administered
therapy.
https://doi.org/10.1371/journal.pmed.1002595.g027
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Conclusion
We have found that TB treatment outcomes improve with the use of adherence interventions
such as patient education and counseling, material support, psychological support interven-
tions, reminders and tracers, and digital health technologies. DOT provided by trained health
workers in the community is associated with better treatment outcomes than DOT provided
by family members or untrained lay workers. DOT provided in the community is associated
with better treatment outcomes than clinic-based DOT. TB patients living with HIV have sig-
nificantly better outcomes when treated with DOT as opposed to SAT. VOT may be an appro-
priate alternative to in-person DOT if the resources for its use are available. More importantly,
a patient-centered approach to TB treatment using a package of adherence interventions tai-
lored to patients’ needs and values leads to improved TB treatment outcomes. The optimal
package of adherence interventions to implement may vary by setting, resources, and the local
epidemiology of TB (e.g., prevalence of comorbidities, including HIV coinfection), among
other factors. The WHO TB treatment guidelines update, for which this review was conducted,
provides additional information on selecting patient-centered approaches for enhancing
adherence [166]. Based on our review, studies on adherence interventions in patients with
MDR-TB as well as cost-effectiveness analyses will be helpful in identifying the optimal inter-
ventions to implement in various settings.
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